Childhood Kidney Diseases

  • 제27권2호
  • /
  • Pages.64-69
  • /
  • 2023
  • /
  • 2384-0242(pISSN)
  • /
  • 2384-0250(eISSN)
대한소아신장학회 (Korean Society of Pediatric Nephrology)
권호 표지
DOI QR코드

DOI QR Code

Comprehensive review of membranoproliferative glomerulonephritis: spotlighting the latest advances in revised classification and treatment

  • Jeong Yeon Kim (Department of Pediatrics, Chungnam National University Hospital)
  • 투고 : 2023.09.15
  • 심사 : 2023.10.19
  • 발행 : 2023.12.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Membranoproliferative glomerulonephritis (MPGN) is a complex group of renal diseases characterized by a specific pattern of glomerular injury that includes thickening of the capillary wall and mesangial expansion, leading to a heterogeneous group of conditions. This review article offers a comprehensive overview of MPGN, its new classification, pathophysiology, diagnostic evaluation, and management options.

키워드

참고문헌

  1. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: a new look at an old entity. N Engl J Med 2012;366:1119-31. https://doi.org/10.1056/NEJMra1108178
  2. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. KDIGO 2021 Clinical practice guideline for the management of glomerular diseases. Kidney Int 2021;100(4S):S1-276. https://doi.org/10.1016/j.kint.2021.05.021
  3. Fogo AB, Lusco MA, Najafian B, Alpers CE. AJKD atlas of renal pathology: membranoproliferative glomerulonephritis. Am J Kidney Dis 2015;66:e19-20. https://doi.org/10.1053/j.ajkd.2015.07.007
  4. Sethi S, Fervenza FC. Membranoproliferative glomerulonephritis: pathogenetic heterogeneity and proposal for a new classification. Semin Nephrol 2011;31:341-8. https://doi.org/10.1016/j.semnephrol.2011.06.005
  5. Xu L, Wei F, Feng J, Liu J, Liu J, Tang X, et al. Characteristics and outcomes of glomerulonephritis with membranoproliferative pattern in children. Transl Pediatr 2021;10:2985-96. https://doi.org/10.21037/tp-21-286
  6. Servais A, Noel LH, Roumenina LT, Le Quintrec M, Ngo S, Dragon-Durey MA, et al. Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. Kidney Int 2012;82:454-64. https://doi.org/10.1038/ki.2012.63
  7. Ruggenenti P, Daina E, Gennarini A, Carrara C, Gamba S, Noris M, et al. C5 convertase blockade in membranoproliferative glomerulonephritis: a single-arm clinical trial. Am J Kidney Dis 2019;74:224-38. https://doi.org/10.1053/j.ajkd.2018.12.046
  8. Angioi A, Fervenza FC, Sethi S, Zhang Y, Smith RJ, Murray D, et al. Diagnosis of complement alternative pathway disorders. Kidney Int 2016;89:278-88. https://doi.org/10.1016/j.kint.2015.12.003
  9. Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, et al. The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group. Nat Rev Nephrol 2019;15:45-59. https://doi.org/10.1038/s41581-018-0077-4
  10. Pickering MC, D'Agati VD, Nester CM, Smith RJ, Haas M, Appel GB, et al. C3 glomerulopathy: consensus report. Kidney Int 2013;84:1079-89. https://doi.org/10.1038/ki.2013.377
  11. Servais A, Fremeaux-Bacchi V, Lequintrec M, Salomon R, Blouin J, Knebelmann B, et al. Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome. J Med Genet 2007;44:193-9. https://doi.org/10.1136/jmg.2006.045328
  12. Bomback AS, Santoriello D, Avasare RS, Regunathan-Shenk R, Canetta PA, Ahn W, et al. C3 glomerulonephritis and dense deposit disease share a similar disease course in a large United States cohort of patients with C3 glomerulopathy. Kidney Int 2018;93:977-85. https://doi.org/10.1016/j.kint.2017.10.022
  13. Ravindran A, Fervenza FC, Smith RJ, De Vriese AS, Sethi S. C3 glomerulopathy: ten years' experience at Mayo Clinic. Mayo Clin Proc 2018;93:991-1008. https://doi.org/10.1016/j.mayocp.2018.05.019
  14. Sethi S, Quint PS, O'Seaghdha CM, Fervenza FC, Bijol V, Dorman A, et al. C4 glomerulopathy: a disease entity associated with C4d deposition. Am J Kidney Dis 2016;67:949-53. https://doi.org/10.1053/j.ajkd.2016.01.012
  15. Mastrangelo A, Serafinelli J, Giani M, Montini G. Clinical and pathophysiological insights into immunological mediated glomerular diseases in childhood. Front Pediatr 2020;8:205.
  16. Cook HT, Pickering MC. Histopathology of MPGN and C3 glomerulopathies. Nat Rev Nephrol 2015;11:14-22. https://doi.org/10.1038/nrneph.2014.217
  17. Tarshish P, Bernstein J, Tobin JN, Edelmann CM Jr. Treatment of mesangiocapillary glomerulonephritis with alternate-day prednisone: a report of the International Study of Kidney Disease in Children. Pediatr Nephrol 1992;6:123-30. https://doi.org/10.1007/BF00866289
  18. Kirpalani A, Jawa N, Smoyer WE, Licht C; Midwest Pediatric Nephrology Consortium. Long-term outcomes of C3 glomerulopathy and immune-complex membranoproliferative glomerulonephritis in children. Kidney Int Rep 2020;5:2313-24. https://doi.org/10.1016/j.ekir.2020.09.019
  19. Fervenza FC, Sethi S, Glassock RJ. Idiopathic membranoproliferative glomerulonephritis: does it exist? Nephrol Dial Transplant 2012;27:4288-94. https://doi.org/10.1093/ndt/gfs288
  20. Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, et al. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference. Kidney Int 2017;91:539-51.
  21. Medjeral-Thomas NR, O'Shaughnessy MM, O'Regan JA, Traynor C, Flanagan M, Wong L, et al. C3 glomerulopathy: clinicopathologic features and predictors of outcome. Clin J Am Soc Nephrol 2014;9:46-53. https://doi.org/10.2215/CJN.04700513
  22. Rabasco C, Cavero T, Roman E, Rojas-Rivera J, Olea T, Espinosa M, et al. Effectiveness of mycophenolate mofetil in C3 glomerulonephritis. Kidney Int 2015;88:1153-60. https://doi.org/10.1038/ki.2015.227
  23. Avasare RS, Canetta PA, Bomback AS, Marasa M, Caliskan Y, Ozluk Y, et al. Mycophenolate mofetil in combination with steroids for treatment of C3 glomerulopathy: a case series. Clin J Am Soc Nephrol 2018;13:406-13. https://doi.org/10.2215/CJN.09080817
  24. Le Quintrec M, Lapeyraque AL, Lionet A, Sellier-Leclerc AL, Delmas Y, Baudouin V, et al. Patterns of clinical response to eculizumab in patients with C3 glomerulopathy. Am J Kidney Dis 2018;72:84-92. https://doi.org/10.1053/j.ajkd.2017.11.019
  25. Nakagawa N, Hasebe N, Hattori M, Nagata M, Yokoyama H, Sato H, et al. Clinical features and pathogenesis of membranoproliferative glomerulonephritis: a nationwide analysis of the Japan renal biopsy registry from 2007 to 2015. Clin Exp Nephrol 2018;22:797-807. https://doi.org/10.1007/s10157-017-1513-7
  26. Lee H, Kim DK, Oh KH, Joo KW, Kim YS, Chae DW, et al. Mortality and renal outcome of primary glomerulonephritis in Korea: observation in 1,943 biopsied cases. Am J Nephrol 2013;37:74-83. https://doi.org/10.1159/000345960